Compare NTLA & AVPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | AVPT |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United States | United States |
| Employees | N/A | 3443 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2016 | N/A |
| Metric | NTLA | AVPT |
|---|---|---|
| Price | $12.72 | $13.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 12 |
| Target Price | ★ $20.02 | $16.64 |
| AVG Volume (30 Days) | ★ 3.1M | 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | $25.00 |
| Revenue Next Year | $62.75 | $19.63 |
| P/E Ratio | ★ N/A | $1,348.94 |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $8.84 |
| 52 Week High | $28.24 | $16.77 |
| Indicator | NTLA | AVPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 54.88 |
| Support Level | $12.55 | $12.92 |
| Resistance Level | $13.88 | $13.71 |
| Average True Range (ATR) | 0.66 | 0.41 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 53.28 | 49.84 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.